Shernan G.Holtan, Chief of the Blood and Marrow Transplant Program at Roswell Park, shared a recent article on X:

“New findings from the Blood and Marrow Transplant Clinical Trials Network 1703 trial: Post-transplant cyclophosphamide (PTCy) lowers patient-reported GVHD symptom burden vs Tac/MTX in the first year after transplant.

Congrats, team.”

“Improved Patient-Reported Outcomes With Post-Transplant Cyclophosphamide: A Quality-of-Life Evaluation and 2-Year Outcomes of BMT CTN 1703”

Authors: Shernan G. Holtan, Javier Bolaños-Meade, Monzr M. Al Malki, Juan Wu, Ran Reshef, Andrew R. Rezvani, Brian C. Shaffer, Melhem M. Solh, Janny M. Yao, Lyndsey Runaas, Hany Elmariah, Karilyn T. Larkin, Najla El Jurdi, Mahasweta Gooptu, Alison W. Loren, Aric C. Hall, Amin M. Alousi, Omer Jamy, William Clark, Leslie Kean, Ami S. Bhatt, Miguel-Angel Perales, Kristy Applegate, Yvonne Adeduni Efebera, Eric Leifer, Richard J. Jones, Mary M. Horowitz, Deborah Mattila, Wael Saber, Mehdi Hamadani and Michael J. Martens

Shernan G. Holtan

More posts featuring Shernan G. Holtan.

Shernan G. Holtan: New findings from the Blood and Marrow Transplant Clinical Trials Network 1703 trial